Researchers have been excited about the medication , a innovative dual agonist showing promising data in clinical trials for body loss . It acts by targeting both pathways : GLP-1 and GIP, that , when https://matherjar947717.get-blogging.com/41204983/this-new-prospect-for-weight-reduction